Direct Evidence from Studies and Labels
Lurbinectedin (brand name Zepzelca) carries a boxed warning for embryo-fetal toxicity based on animal data and its mechanism as a DNA-damaging agent. In rats, intravenous doses about 0.1 times the human equivalent caused fetal malformations including absence of tail, anasarca, amniotic fluid retention, and reduced skeletal ossification. No human data on fetal abnormalities exist, as pregnant women are excluded from trials.[1][2]
What Happens in Human Pregnancies?
No documented cases of lurbinectedin-induced fetal abnormalities appear in clinical trials, post-marketing surveillance, or registries. The prescribing information notes "there are no available data on Zepzelca use in pregnant women to inform the drug-associated risk," relying solely on genotoxic animal findings. One case report exists of inadvertent exposure in early pregnancy, but it lacks confirmed fetal outcomes and does not document abnormalities.[3]
Why the Pregnancy Category and Warnings?
Lurbinectedin is pregnancy category not assigned (per old FDA system) and classified as high risk by manufacturers. It inhibits DNA repair, mimicking alkylating agents known for teratogenicity. Women of reproductive potential must use effective contraception during treatment and for 6 months after; men for 4 months. Verify pregnancy status before starting.[1][2]
Clinical Trial Exclusions and Real-World Data Gaps
Trials like the pivotal PM14-501 study excluded pregnant or breastfeeding patients, yielding no human fetal exposure data. Post-approval, FDA Adverse Event Reporting System (FAERS) shows minimal pregnancy-related entries for lurbinectedin, none specifying abnormalities as of latest reviews. Limited real-world use since 2020 approval means rare exposures go underreported.[4]
Alternatives for Patients of Childbearing Age
Options like topotecan or standard platinum-etoplin combos lack lurbinectedin's specific warnings but carry similar embryo-fetal risks. Discuss fertility preservation pre-treatment; embryo cryopreservation is recommended for those planning future pregnancy.[1]
[1]: Zepzelca Prescribing Information (FDA)
[2]: Drugs.com - Lurbinectedin Pregnancy
[3]: PubMed - Lurbinectedin Case Report (2022)
[4]: FDA FAERS Database Query (via OpenFDA)